BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, May 23, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

Feb. 18, 2025

View Archived Issues
VAripulse

J&J resumes US Varipulse sales, but will it matter?

Nearly six weeks after Johnson & Johnson paused the U.S. external evaluation of its Varipulse pulsed field ablation catheter to investigate several neurovascular events in initial cases, the med-tech giant resumed its limited market release with revised global instructions for use. Read More
Hand holding a pink slip or termination notice against a blurred office background

Thousands of US HHS staff terminated in name of efficiency

As part of a U.S. government-wide reduction in force aimed at restructuring and streamlining federal agencies, 5,200 Health and Human Services employees reportedly received their pink slips over the weekend, with 1,165, or 22%, of those at the NIH. Read More
Germitec Chronos

Germitec raises $30M to bring UV-C disinfection tech to US

Germitec SA raised $30 million in a series B financing round to bring Chronos, its chemical-free, ultraviolet-C (UV-C)-based disinfection system for ultrasound probes, to the U.S. market. Read More
Dongkook hq

Dongkook Life Science secures ₩18B IPO

Dongkook Life Science Co. Ltd. (DKLS) priced a ₩18 billion (US$12.5 million) IPO on the Korea Exchange as South Korea’s first med-tech listing of the year. Read More
Stock merger illustration

Med-tech opens 2025 with $4.5B in January M&As

Med-tech M&As saw a strong start in January, totaling $4.51 billion, a significant jump from $18 million in December 2024 but lower than November’s $12.68 billion. Dealmaking reached $57.94 billion in 2024, averaging about $4.8 billion per month. Read More

Med-tech gainers and losers for Feb. 10-14, 2025

The top 10 med-tech stock gainers and losers for the week. Read More
World trade illustration

Five med-tech trends to watch in 2025

The Clarivate Medtech Trends to Watch in 2024 report noted the resilience of the medtech sector in the face of changing macroeconomic factors and the preparation required to navigate the market’s many complexities. It is likely that 2025 will be no different. Read More

Holiday notice

BioWorld's offices were closed in observance of Presidents Day in the U.S. No issue was published Monday, Feb. 17. Read More

Financings for Feb. 18, 2025

Med-tech firms raising money in public or private financings, including: Endovascular Engineering, Quokka Care, Spectral AI, Subsense. Read More

In the clinic for Feb. 18, 2025

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Syra. Read More

Other news to note for Feb. 18, 2025

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Diablo Clinical Research, Emboa, Flourish Research, Pavmed. Read More

Regulatory actions for Feb. 18, 2025

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aidoc, Bioretec, MED-EL, Navi Medical. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 22, 2026.
  • Acid alpha-glucosidase molecular structure isolated on black

    ‘Detargeted’ targeted gene therapy improves activity in Pompe

    BioWorld
    A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 19, 2026
  • Nxera Pharma prepares and tests new GPR17 antagonists

    BioWorld Science
    Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
  • Genescience presents STAT6 degrader for atopic dermatitis

    BioWorld Science
    Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing